Symbol="CLLS"
AssetType="Common Stock"
Name="Cellectis SA"
Description="Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France."
CIK="1627281"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="8 RUE DE LA CROIX JARRY, PARIS, LLE-DE-FRANCE, FR"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="120061000"
EBITDA="-73291000"
PERatio="None"
PEGRatio="0"
BookValue="2.046"
DividendPerShare="0"
DividendYield="0"
EPS="-2.18"
RevenuePerShareTTM="0.542"
ProfitMargin="0"
OperatingMarginTTM="-3.272"
ReturnOnAssetsTTM="-0.174"
ReturnOnEquityTTM="-0.607"
RevenueTTM="25483000"
GrossProfitTTM="23952000"
DilutedEPSTTM="-2.18"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.063"
AnalystTargetPrice="7.8"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="4.479"
PriceToBookRatio="0.75"
EVToRevenue="5.07"
EVToEBITDA="-0.64"
Beta="2.001"
num_52WeekHigh="4.1"
num_52WeekLow="1.68"
num_50DayMovingAverage="2.038"
num_200DayMovingAverage="2.226"
SharesOutstanding="55584000"
DividendDate="None"
ExDividendDate="None"
symbol="CLLS"
open="2.17"
high="2.21"
low="2.00"
price="2.16"
volume="143983.00"
latest_trading_day="2023-07-28"
previous_close="2.21"
change="-0.05"
change_percent="-2.2624%"
aroon_positive_momentum_days="44"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="44"
Volume_recent_avg="64409"
Change_recent_avg="0.01"
Delta_recent_avg="0.11"
Variance_recent_avg="0.05"
Change_ratio_recent_avg="-0.12"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="44"
Aroon_momentum_negative="56"
image_negative_thumbnail_id_1="1151"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0184.jpeg"
image_negative_thumbnail_id_2="1161"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0195.jpeg"
image_neutral_thumbnail_id_1="534"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0065.jpeg"
image_neutral_thumbnail_id_2="563"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0036.jpeg"
image_positive_thumbnail_id_1="671"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0037.jpeg"
image_positive_thumbnail_id_2="682"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0026.jpeg"
image_professor_thumbnail_id_1="1171"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0005.jpeg"
image_professor_thumbnail_id_2="1170"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0004.jpeg"
